MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Search

Lyell Immunopharma Inc

Chiusa

25.15 1.33

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

23.95

Massimo

25.46

Metriche Chiave

By Trading Economics

Entrata

3.8M

-39M

Vendite

7K

15K

EPS

-2.13

Margine di Profitto

-258,973.333

Dipendenti

300

EBITDA

6.3M

-36M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+12.83% upside

Dividendi

By Dow Jones

Utili prossimi

9 mar 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

165M

505M

Apertura precedente

23.82

Chiusura precedente

25.15

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Lyell Immunopharma Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 gen 2026, 23:07 UTC

Utili

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 gen 2026, 21:27 UTC

Utili

Texas Instruments 4Q Sales Rise, Profit Falls

27 gen 2026, 23:55 UTC

Discorsi di Mercato

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 gen 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 gen 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 gen 2026, 23:39 UTC

Discorsi di Mercato

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 gen 2026, 23:20 UTC

Utili

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 gen 2026, 23:20 UTC

Utili

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 gen 2026, 23:19 UTC

Utili

SK Innovation Posts Net Loss for Second Consecutive Year

27 gen 2026, 23:19 UTC

Utili

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 gen 2026, 23:18 UTC

Utili

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 gen 2026, 23:18 UTC

Utili

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 gen 2026, 23:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 gen 2026, 23:11 UTC

Discorsi di Mercato

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 gen 2026, 23:07 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 gen 2026, 22:17 UTC

Discorsi di Mercato

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 gen 2026, 22:06 UTC

Utili

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 gen 2026, 21:51 UTC

Utili

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

27 gen 2026, 21:43 UTC

Utili

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 gen 2026, 21:41 UTC

Utili

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 gen 2026, 21:38 UTC

Utili

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 gen 2026, 21:32 UTC

Utili

Ampol: Modest Profit From F&I International in 2025

27 gen 2026, 21:32 UTC

Utili

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 gen 2026, 21:31 UTC

Utili

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 gen 2026, 21:31 UTC

Utili

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 gen 2026, 21:30 UTC

Utili

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 gen 2026, 21:29 UTC

Utili

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 gen 2026, 21:29 UTC

Utili

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 gen 2026, 21:28 UTC

Utili

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Confronto tra pari

Modifica del prezzo

Lyell Immunopharma Inc Previsione

Obiettivo di Prezzo

By TipRanks

12.83% in crescita

Previsioni per 12 mesi

Media 28.5 USD  12.83%

Alto 45 USD

Basso 12 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lyell Immunopharma Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

2 ratings

1

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

0.4217 / 0.4691Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

help-icon Live chat